Please use this identifier to cite or link to this item:
https://doi.org/10.1182/blood-2011-07-367326
Title: | Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias | Authors: | Nicolini, F.E. Basak, G.W. Soverini, S. Martinelli, G. Mauro, M.J. Müller, M.C. Hochhaus, A. Chuah, C. Dufva, I.H. Rege-Cambrin, G. Saglio, G. Michallet, M. Labussière, H. Morisset, S. Hayette, S. Etienne, G. Olavarria, E. Zhou, W. Peter, S. Apperley, J.F. Cortes, J. |
Issue Date: | 17-Nov-2011 | Citation: | Nicolini, F.E., Basak, G.W., Soverini, S., Martinelli, G., Mauro, M.J., Müller, M.C., Hochhaus, A., Chuah, C., Dufva, I.H., Rege-Cambrin, G., Saglio, G., Michallet, M., Labussière, H., Morisset, S., Hayette, S., Etienne, G., Olavarria, E., Zhou, W., Peter, S., Apperley, J.F., Cortes, J. (2011-11-17). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118 (20) : 5697-5700. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2011-07-367326 | Abstract: | T315I + Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited.We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL T315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome-positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P ∇ .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P ∇ .0011) and unrelated stem cell donor (hazard ratio 2.98, P ∇ .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABL T315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors. © 2011 by The American Society of Hematology. | Source Title: | Blood | URI: | http://scholarbank.nus.edu.sg/handle/10635/124782 | ISSN: | 00064971 | DOI: | 10.1182/blood-2011-07-367326 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.